[go: up one dir, main page]

PE20090513A1 - Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3 - Google Patents

Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3

Info

Publication number
PE20090513A1
PE20090513A1 PE2008001318A PE2008001318A PE20090513A1 PE 20090513 A1 PE20090513 A1 PE 20090513A1 PE 2008001318 A PE2008001318 A PE 2008001318A PE 2008001318 A PE2008001318 A PE 2008001318A PE 20090513 A1 PE20090513 A1 PE 20090513A1
Authority
PE
Peru
Prior art keywords
trans
benzoyl
receptors
cyclohexyl
ht2a
Prior art date
Application number
PE2008001318A
Other languages
English (en)
Inventor
Luca Gobbi
Georg Jaeschke
Sarmiento Rosa Maria Rodriguez
Lucinda Steward
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20090513A1 publication Critical patent/PE20090513A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA (I): DONDE R1 ES II; A ES ARILO O HETEROARILO SUSTITUIDO O NO POR CN, HALOGENO, ALQUILO(C1-C6), ENTRE OTROS; m ES 1-3; n ES 0-5; o ES 0-2; R2 ES H, OH, ALQUILO(C1-C6), ENTRE OTROS; R3 ES HALOALQUILO(C1-C6), HALOALCOXI(C1-C6)- OXO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-TRANS-(4-{2-[4-(4-FLUOR-BENZOIL)-PIPERIDIN-1-IL]-ETIL}-CICLOHEXIL)-2-CIS/TRANS-(4-HIDROXI-CICLOHEXIL)-ACETAMIDA; N-TRANS-(4-{2-[4-(4-FLUOR-BENZOIL)-PIPERIDIN-1-IL]-ETIL}-CICLOHEXIL)-2-(4-TRANS-HIDROXI-4-METIL-CICLOHEXIL)-ACETAMIDA; ENTRE OTROS.TAMBIEN SE REFIERE UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO PARA SINTETIZAR LOS INTERMEDIOS. DICHOS COMPUESTOS TIENEN ACTIVIDAD SOBRE LOS RECEPTORES DE LA DOPAMINA D3 Y SEROTININA (5-HIDROXITRIPTAMINA; 5-HT) UTILES EN EL TRATAMIENTO DE TRANSTORNOS PSICOTICOS TAL COMO LA DEPRESION
PE2008001318A 2007-08-09 2008-08-07 Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3 PE20090513A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114119 2007-08-09

Publications (1)

Publication Number Publication Date
PE20090513A1 true PE20090513A1 (es) 2009-04-29

Family

ID=39865594

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001318A PE20090513A1 (es) 2007-08-09 2008-08-07 Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3

Country Status (16)

Country Link
US (1) US8097637B2 (es)
EP (1) EP2185513B1 (es)
JP (1) JP5296073B2 (es)
KR (1) KR101171467B1 (es)
CN (1) CN101778820B (es)
AR (1) AR067873A1 (es)
AT (1) ATE512137T1 (es)
AU (1) AU2008285729B2 (es)
BR (1) BRPI0814999A2 (es)
CA (1) CA2694057A1 (es)
CL (1) CL2008002310A1 (es)
ES (1) ES2366766T3 (es)
MX (1) MX2010001195A (es)
PE (1) PE20090513A1 (es)
TW (1) TW200914422A (es)
WO (1) WO2009019174A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2396265C2 (ru) 2006-02-17 2010-08-10 Ф. Хоффманн-Ля Рош Аг Производные бензоилпиперидина в качестве модуляторов рецепторов 5ht2 и d3
KR101169518B1 (ko) * 2007-07-26 2012-07-27 에프. 호프만-라 로슈 아게 5-ｈｔ2ａ 및 ｄ3 수용체의 이중 조절제
US8586579B2 (en) 2010-06-21 2013-11-19 Hoffmann-La Roche Inc. Anellated pyridine compounds
US8470828B2 (en) 2010-07-06 2013-06-25 Hoffmann-La Roche Inc. Anellated pyridine compounds
US8921397B2 (en) * 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds
WO2013086266A2 (en) * 2011-12-08 2013-06-13 The Board Of Regents Of The University Of Texas System Allosteric modulators of 5-hydroxytryptamine 2c receptor (5-ht2cr)
PE20171119A1 (es) 2014-12-12 2017-08-08 Japan Tobacco Inc Compuestos de dihidropirimidin-2-ona y sus usos medicos
CN117550989B (zh) * 2023-11-14 2024-09-27 泰州精英化成医药科技有限公司 一种反式-2-(4-氨基环己基)乙酸乙酯盐酸盐的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717479B1 (fr) * 1994-03-18 1996-06-07 Pf Medicament Nouvelles 3-(omega-benzoylpipéridino) alcoyl)-4H-Benzopyran-4-ones, leur préparation et leur application en thérapeutique.
HUP0103986A2 (hu) * 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
AU2002366766A1 (en) * 2001-12-13 2003-07-09 Sumitomo Pharmaceuticals Co., Ltd. Serotonine reuptake inhibitor
RU2396265C2 (ru) * 2006-02-17 2010-08-10 Ф. Хоффманн-Ля Рош Аг Производные бензоилпиперидина в качестве модуляторов рецепторов 5ht2 и d3

Also Published As

Publication number Publication date
ES2366766T3 (es) 2011-10-25
CN101778820B (zh) 2012-12-05
EP2185513B1 (en) 2011-06-08
CL2008002310A1 (es) 2009-05-29
CA2694057A1 (en) 2009-02-12
US20090042943A1 (en) 2009-02-12
US8097637B2 (en) 2012-01-17
AU2008285729A1 (en) 2009-02-12
AR067873A1 (es) 2009-10-28
KR20100029850A (ko) 2010-03-17
MX2010001195A (es) 2010-03-01
JP2010535735A (ja) 2010-11-25
AU2008285729B2 (en) 2012-11-01
CN101778820A (zh) 2010-07-14
BRPI0814999A2 (pt) 2015-02-03
WO2009019174A1 (en) 2009-02-12
ATE512137T1 (de) 2011-06-15
TW200914422A (en) 2009-04-01
JP5296073B2 (ja) 2013-09-25
KR101171467B1 (ko) 2012-08-07
EP2185513A1 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
PE20090513A1 (es) Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20142340A1 (es) Inhibidores de bromodominios
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
PE20140934A1 (es) Derivados de pirazol
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
PE20080671A1 (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
PE20140918A1 (es) Compuestos de benzoxepina inhibidores de la pi3k
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
PE20080552A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
PE20151601A1 (es) Compuestos novedosos de pirimidina y piridina y su uso
PE20170682A1 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias
PE20120113A1 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
PE20090892A1 (es) MODULADORES DUALES DE LOS RECEPTORES 5-HT2a Y D3
AR072793A1 (es) Compuestos de aril isoxazol con actividades antitumorales
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
AR077227A1 (es) Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende

Legal Events

Date Code Title Description
FD Application declared void or lapsed